期刊文献+

β受体阻滞剂在心力衰竭中的作用 被引量:4

The Role of β-blockers in Heart Failure
下载PDF
导出
摘要 目的:研究β受体阻滞剂在心力衰竭及心律失常中的临床治疗作用。方法:选取笔者所在医院2012年1-12月收治的324例慢性心力衰竭患者作为研究对象,采用随机抽签法将其分为对照组和A、B组各108例,对照组给予安慰剂治疗,A组给予美托洛尔治疗,B组给予卡维地洛治疗,观察比较三组患者的死亡情况和再住院情况。结果:治疗8周后,A组的猝死率、心衰死亡率、心血管死亡率、总死亡率和再住院率分别为9.26%、8.33%、8.33%、28.70%、22.22%;B组为2.78%、1.85%、1.85%、7.41%、12.04%,两组各观察指标均明显低于对照组,且B组以上指标均明显低于A组,差异均有统计学意义(P<0.05)。结论:β受体阻滞剂在治疗心力衰竭和心律失常中具有降低死亡率和再住院率的优点,但不同类型β受体阻滞剂治疗效果存在一定差异,在临床用药过程中要综合考虑,合理用药。 Objective:To research the clinical effect of β-blockers in heart failure and arrhythmia.Method:324 patients with chronic heart failure admitted to our hospital from January 2012 to December 2012 were selected,they were divided into the control group,the group A and the group B with the method of random sampling,108 cases in each group.The control group was given Placebo for treatment,the group A was given Metoprolol for treatment,the group B was given Carvedilol for treatment.The death and readmission of the three groups were observed and compared.Result:After 8 weeks of treatment,the sudden death,heart failure caused mortality,cardiovascular mortality,total mortality and readmission rates in group A were 9.26%,8.33%,8.33%,28.70%,22.22%,those in the group B were 2.78%,1.85%,1.85%,7.41%,12.04%.The observed indices of two groups were significantly lower than the control group,and the above indexes of group B were significantly lower than group A,the differences were statistically significant(P〈0.05).Conclusion:β-blockers has the advantage of reducing mortality and readmission rates in the treatment of heart failure and cardiac arrhythmias,but there are some differences between different types of β-blocker treatment,in the clinical course of medication to be considered,rational drug use.
作者 苏永军
机构地区 元谋县中医医院
出处 《中外医学研究》 2014年第35期33-34,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 Β受体阻滞剂 心力衰竭 心律失常 作用 β-blockers Heart failure Arrhythmia Role
  • 相关文献

参考文献11

二级参考文献111

共引文献265

同被引文献59

  • 1王晓梅,吴焕淦,赵琛,周爽.红景天抗衰老作用研究概况[J].江苏中医药,2006,27(4):60-62. 被引量:15
  • 2陆在英,钟南山.内科学.北京:人民卫生出版社.[M].2008.4.第7版.17-21,61-78. 被引量:15
  • 3无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3680
  • 4Maeder MT, Rickli H, Pfisterer ME, et al. Incidence, clinical predictors and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J, 2012,163:407-414. 被引量:1
  • 5Shore S, Aggarwal V, Zolty R. Carvedilol or sustained-release metoprolol for congestive heart failure: a comparative effective- ness analysis. J Card Fail,2012,18:919-924. 被引量:1
  • 6Shen X, Nair CK, Aronow WS, et al. Effect of carvedilol versus metoprolol CR/XL on mortality in patients with heart failure treated with cardiac resynchronization therapy: a COX multivari- ate regression analysis. Am J Ther, 2013,20 : 247-253. 被引量:1
  • 7Yancy CW, Jessup M, Bozkart B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Asso- ciation Task Force on Practice Guidelines. J Am Coil Cardiol, 2013,62 : e147-239. 被引量:1
  • 8中华医学会心血管分学会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014.中华心血管杂志,2014,42:98-122. 被引量:1
  • 9Babick A, Elimban V, Zieroth S, et al. Reversal of cardiac dys- function and subcellular alterations by metoprolol in heart failure due to myocardial infarction. J Cell Physiol,2013,228:2063- 2070. 被引量:1
  • 10James L, Januzzi Jr. The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arc Cardiovas Dis, 2012,105:40-50. 被引量:1

引证文献4

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部